{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"17"}],"title":"0: Fully active, able to carry on all pre-disease performance without restriction"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"title":"1: Restricted in physically strenuous activity and able to carry out light or sedentary work"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"2: Ambulatory and capable of all self-care but unable to carry out any work activities"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"38"}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"title":"Grade 0 at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"1"}],"title":"0: Fully active, able to carry on all pre-disease performance without restriction"},{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}],"title":"1: Restricted in physically strenuous activity and able to carry out light or sedentary work"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"2: Ambulatory and capable of all self-care but unable to carry out any work activities"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Grade 1 at baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"75"}],"units":"Participants"}],"description":"The ECOG scale of performance status described the level of functioning of participants in terms of their ability to care for themselves, daily activity, and physical ability. The ECOG performance was recorded as per ECOG performance status grades ranging from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead).","groups":[{"description":"Ruxolitinib at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS) included all participants to whom study treatment was assigned by randomization and had valid measurements for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 28","title":"Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to Week 28","type":"SECONDARY","unitOfMeasure":"Participants"}